ConductScience.org, home

Paper42968166PubMed

Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact.

Mazzocca A and 11 others. J Transl Med, 2026.

Cite this record

ConductScience Library. Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact. Papers, record 42968166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42968166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact.
Journal
J Transl Med
Year
2026
Publication types
Journal Article, Review
Revised in PubMed
2026-11-05

Source PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mazzocca AAlessandro
2Calagna SSilvia
3Mingo ECEmanuele Claudio
4Cavaliere SSilvia
5Iuliani MMichele
6D'Amato ALAgostina Lagodin
7Scarpato LLuigi
8Pantano FFrancesco
9Tonini GGiuseppe
10Vincenzi BBruno
11Cortellini AAlessio
12Ascierto PAPaolo Antonio

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Immune Checkpoint InhibitorsMajor topic
Translational Research, BiomedicalMajor topic
Immune Checkpoint ProteinsMajor topic
Humans
Animals
Immunotherapy

Source PubMed

Download CSV of topics

References84

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133811048Development of Immunotherapy Combination Strategies in Cancer.Cancer Discov2021https://conductscience.org/library/papers/33811048PubMed
240890162TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies.Cell Death Dis2025https://conductscience.org/library/papers/40890162PubMed
337884747Alleviating hypoxia to improve cancer immunotherapy.Oncogene2023https://conductscience.org/library/papers/37884747PubMed
438057451Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.Nat Rev Immunol2024https://conductscience.org/library/papers/38057451PubMed
534093577The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.Front Immunol2021https://conductscience.org/library/papers/34093577PubMed
633485464First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021https://conductscience.org/library/papers/33485464PubMed
740552922Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.Clin Cancer Res2025https://conductscience.org/library/papers/40552922PubMed
840469190Role of TGFβ-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy.Front Oncol2025https://conductscience.org/library/papers/40469190PubMed
934460110Metabolic checkpoints and novel approaches for immunotherapy against cancer.Int J Cancer2022https://conductscience.org/library/papers/34460110PubMed
1037857711The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.Nat Med2023https://conductscience.org/library/papers/37857711PubMed
1137356739Reprogramming of cancer-associated fibroblasts combined with immune checkpoint inhibitors: A potential therapeutic strategy for cancers.Biochim Biophys Acta Rev Cancer2023https://conductscience.org/library/papers/37356739PubMed
1241613119Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition.Front Immunol2025https://conductscience.org/library/papers/41613119PubMed
1333285141Enhancing anti-tumour efficacy with immunotherapy combinations.Lancet2021https://conductscience.org/library/papers/33285141PubMed
1440171330Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications.Immunotargets Ther2025https://conductscience.org/library/papers/40171330PubMed
1540234667First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors.Br J Cancer2025https://conductscience.org/library/papers/40234667PubMed
1639426385
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Lancet2024https://conductscience.org/library/papers/39426385PubMed
1741708938Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?Br J Cancer2026https://conductscience.org/library/papers/41708938PubMed
1826558876CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.Am J Clin Oncol2016https://conductscience.org/library/papers/26558876PubMed
1936933320Anti-TIGIT therapies for solid tumors: a systematic review.ESMO Open2023https://conductscience.org/library/papers/36933320PubMed
2041109920Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.Nat Med2025https://conductscience.org/library/papers/41109920PubMed

See all 84 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42968166

GET https://conductscience.org/api/papers/v1/42968166/references?page=2